New combo therapy tested for Tough-to-Treat returning breast cancer
Disease control
Not yet recruiting
This study is for people with a specific type of advanced breast cancer (HR+, HER2-) that has spread and has come back after they finished a prior course of hormone-blocking pills. It will test if adding a drug called ribociclib to standard hormone therapy (fulvestrant) works bet…
Phase: PHASE2 • Sponsor: Yeon Hee Park • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC